Trading Members and Custodians are requested to note that Securities Exchange Board of India (SEBI) has issued Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and vide its circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 and no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016. The Exchange vide its notice no. 20170210-16 dated Feb 10, 2017, has issued Revised Guidelines of Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and Delisting.

All Market Participants are hereby informed that Novartis India Limited (the “Company”), has announced cash offer to buyback not exceeding 34,50,000 (Thirty Four Lakhs And Fifty Thousand) fully paid-up equity shares of face value Rs 5/- each, representing 12.26% of the total number of equity shares in the present issued, subscribed and paid-up equity share capital of the company, from all the existing shareholders / beneficial owners of equity shares of the Company as on the record date i.e. Friday, December 8, 2017, on a proportionate basis, through the “Tender Offer” route at a price of Rs 670 (Rupees Six Hundred And Seventy Only) per equity share for an aggregate maximum amount of Rs 231,15,00,000 (Rupees Two Hundred And Thirty One Crores Fifteen Lakhs Only) from January 04, 2018 to January 17, 2018.

Market participants are further requested to note that this offer will be as per the Revised Guidelines of SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated Dec 09, 2016 and Exchange notice no. 20170210-16 dated Feb 10, 2017 and the details of this Offer to Buy would be available on BSE Website – www.bseindia.com.

Girish Joshi

Sr. General Manager

Listing Sales & Ops

December 29, 2017